High-dose regimen to achieve novel target trough concentration in teicoplanin

Wilson, 2000, Clinical pharmacokinetics of teicoplanin, Clinical Pharmacokinet, 39, 167, 10.2165/00003088-200039030-00001

Svetitsky, 2009, Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis, Antimicrob Agents Chemother, 53, 4069, 10.1128/AAC.00341-09

Schaison, 2000, Teicoplanin in the treatment of serious infection, J Chemother, 12, 26

Harding, 2000, Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome, J Antimicrob Chemother, 45, 835, 10.1093/jac/45.6.835

Begg, 2000, The therapeutic monitoring of antimicrobial agents, Br J Clin Pharmacol, 52, 35S, 10.1046/j.1365-2125.2001.00377.x

Tobin, 2010, Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service, J Antimicrob Chemother, 65, 2155, 10.1093/jac/dkq266

Rybak, 2009, Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, Am J Health Syst Pharm, 66, 82, 10.2146/ajhp080434

Pea, 2003, Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose, J Antimicrob Chemother, 51, 971, 10.1093/jac/dkg147

Ahn, 2011, Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic fever, Yonsei Med J, 52, 616, 10.3349/ymj.2011.52.4.616

Brink, 2008, Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis, Int J Antimicrob Agents, 32, 455, 10.1016/j.ijantimicag.2008.05.012

Matsumoto, 2010, Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections, J Infect Chemother, 16, 193, 10.1007/s10156-010-0038-8

Ueda, 2012, Evaluation of teicoplanin dosing designs to achieve a new target trough concentration, J Infect Chemother, 18, 296, 10.1007/s10156-011-0325-z

Pea, 2004, Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages, Clin Pharmacokinet, 43, 405, 10.2165/00003088-200443060-00004

Wang, 2012, Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections, Basic Clin Pharmacol Toxicol, 110, 416, 10.1111/j.1742-7843.2012.00862.x

Mimoz, 2006, Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia, Intensive Care Med, 32, 775, 10.1007/s00134-006-0136-3

Matthews, 2007, Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic?, J Infect, 55, 408

Niwa, 2010, Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics, Int J Antimicrob Agents, 35, 507, 10.1016/j.ijantimicag.2009.12.018

Lamont, 2009, Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme, J Antimicrob Chemother, 64, 181, 10.1093/jac/dkp147

Rybak, 1991, Clinical evaluation of teicoplanin fluorescence polarization immunoassay, Antimicrob Agents Chemother, 35, 1586, 10.1128/AAC.35.8.1586

Senior, 2009, Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests?, Clin Pharmacol Ther, 85, 331, 10.1038/clpt.2008.262